Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Downgraded By Second Bank in Two Months

NEW YORK, Aug. 4 (GenomeWeb News) - Merriman Curhan Ford today downgraded Ciphergen shares to 'sell' from 'neutral,' the the brokerage and investment bank said.


The downgrade comes as Ciphergen shares continue to slide after the company reported lackluster sales during the second quarter.


The downgrade is the second in as many months to hit Ciphergen: Piper Jaffray on July 1 downgraded the stock to 'underperform' from 'outperform.'


Shares in the Fremont, Calif.-based protein chip company were trading down 15.5 percent, or $.49, at $2.87 on the Nasdaq exchange late this morning. The shares closed at $4.10 on July 30. Ciphergen issued its second-quarter earnings after the market closed that day.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.